Please assess the completion status of the following clinical trial:

Trial Title: Trial of Taselisib in Overgrowth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have given, or their legal representative has given, written informed consent to participate~* Aged 16 years to 65 years inclusive~* Male or female~* Post-zygotic PIK3CA mutation~* Clinically stable in the opinion of the investigator~* Participant Pregnancy and contraception:~  o Female participants of child bearing potential must use an effective method of contraception during treatment and for at least 3 months after the final dose of taselisib. Acceptable methods are:~* True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the trial)~* Oral contraceptive (either combined or progestogen alone)~* Contraceptive implant, injections or patches~* Vaginal ring~* Intrauterine device (IUD, coil or intrauterine system)~* Condom and cap~* Diaphragm plus spermicide~  * A female participant of child bearing potential is defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 12 consecutive months if aged 55 years or older.~ * Men must use one of the following, reliable forms to contraception for the entire duration of treatment and for 3 months after the final dose of taselisib:~* Condom plus spermicide even if female partner is using another method of contraception (Men should also use a condom to protect male partners, or female partners who are pregnant or breast feeding, from exposure to the Trial medicine in semen).~* True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the Trial)~Exclusion Criteria:~* Pregnant or breastfeeding~* HIV infection~* Hypersensitivity to taselisib or any of its excipients~* Any current medical disorder or medication likely to impair ability to follow the trial protocol safely and effectively~* Are concurrently taking an mTOR inhibitor or any other small molecule inhibitor of the PI3K-AKT signalling pathway~* Unable or unwilling to give informed consent~* Sirolimus or taselisib treatment in 12 weeks prior to screening~* Treatment with a strong inducer or inhibitor of CYP3A4 without the possibility to stop this medication within the week prior to the screening. This includes:~* Macrolide Antibiotics: clarithromycin, telithromycin, erythromycin, troleandomycin~* Gastrointestinal prokinetic agents: metoclopramide.~* Antifungals: itraconazole, ketoconazole, fluconazole, voriconazole, clotrimazole~* Calcium channel blockers: verapamil, diltiazem, nicardipine~* Grapefruit containing foods/drinks~* Anticonvulsants: carbamazepine, phenobarbital, phenytoin~* Antibiotics: rifampicin, rifabutin, rifapentine~* Herbal preparations: St. John's wort (Hypericum perforatum). Other drugs: bromocriptine, cimetidine, danazol, cyclosporine, lansoprazole, calcium containing antacids.~* Inability to attend trial visits~* If less than 3 months post- major surgery at screening~* Any past medical history of inflammatory bowel disease or chronic diarrhoea of unknown aetiology~* History of type 1 or type 2 diabetes mellitus requiring insulin, GLP-1 analogues or oral hypoglycaemic agents.~* History of inflammatory bowel disease, ischemic colitis, or colitis of unknown origin.~* Fasting blood glucose \> 6.9 mmol/l~* HbA1C \> 6%~* Long QT, congenital or acquired~* Active pneumonitis~* Patients who require daily supplemental oxygen~* Inadequate renal function defined as creatinine clearance or radioisotope GFR \< 60ml/min/1.73 m²~* Inadequate liver function defined as:~* Total bilirubin \> 2.0 x ULN or conjugated bilirubin \> 2.0 x ULN for age, and~* SGPT (ALT) or SGOT (AST) ≥ 1.5 x ULN for age, and~* Serum albumin \< 30 g/L~* Inadequate fasting LDL cholesterol \> 4.2 mmol/l~* Deprived of freedom by an administrative or court order, or benefiting from a system of legal protection (tutorship, curatorship or safeguard of justice).~* Not covered by health insurance

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy